Understanding the Rise of Migraine Prevention Shots
Migraine headaches affect over 40 million adults in the United States. For years, treatment relied on daily pills or emergency medications that only worked after pain started. Today, a new generation of FDA-approved injections offers a different approach. These shots focus on prevention, targeting the biological pathways that trigger migraine attacks before they begin. In 2024, these treatments are more accessible than ever, with clearer insurance pathways and manufacturer savings programs that lower monthly costs. Understanding how they work, who qualifies, and what to expect financially can help you make an informed decision about your headache care.
How FDA-Approved Migraine Shots Work
Migraine attacks are closely linked to a protein called calcitonin gene-related peptide, or CGRP. When CGRP levels rise in the brain and surrounding nerves, it causes blood vessels to widen and triggers pain signals. The new migraine shots are designed to block CGRP or its receptor, effectively turning down the volume on migraine activity. These medications are classified as CGRP monoclonal antibodies. They do not work like traditional pain relievers. Instead, they build up in your system to reduce the frequency and severity of attacks over time.
The Leading Injectable Options Available in 2024
- Emgality (galcanezumab): A monthly self-injection given under the skin. Available in 120 mg and 240 mg doses. The 240 mg dose is typically used for the first month, followed by 120 mg monthly.
- Ajovy (fremanezumab): Offers flexible dosing. You can choose a 225 mg dose once a month or a 142.5 mg dose every two months. It is also a subcutaneous injection.
- Vyepti (eptinezumab): The only FDA-approved migraine shot given as an intravenous infusion in a clinic or hospital setting. You receive a 100 mg dose every 12 weeks.
All three medications carry FDA approval for preventing migraines in adults. They are not intended to stop a migraine attack once it has already started. Clinical trials show that patients typically see a 50 percent reduction in headache days within the first three months of consistent use.
Who Qualifies for Migraine Prevention Injections?
These treatments are not for everyone, but they are designed for specific migraine patterns. Neurologists and primary care providers usually recommend them for adults who meet one of the following criteria:
- Episodic Migraine: You have 4 to 14 headache days per month. Prevention shots can help keep attacks from becoming chronic.
- Chronic Migraine: You experience 15 or more headache days per month, with at least 8 of those days having migraine features. These shots are a first-line preventive option for chronic cases.
- Failed Oral Medications: You have tried and could not tolerate or get relief from traditional preventives like beta-blockers, anticonvulsants, or antidepressants.
Before starting, your provider will review your medical history. These shots are generally safe for people with high blood pressure, diabetes, or mild anxiety. They are not recommended if you have a known allergy to any ingredient in the pen or syringe, or if you are pregnant or planning to become pregnant, due to limited safety data in that population.
Insurance Coverage and Medicare Rules
Insurance coverage for migraine prevention shots has improved significantly, but approval is not automatic. Most commercial health plans require prior authorization. This means your provider must submit clinical notes, a treatment history, and a letter of medical necessity to prove the shot is appropriate for your case. Step therapy is also common. Insurers may require you to try two oral preventives for 60 to 90 days before approving an injection.
How Medicare Handles Migraine Injections
Medicare coverage depends on how the medication is administered. Vyepti is covered under Medicare Part B because it is given as a clinic infusion. You will typically pay 20 percent of the Medicare-approved amount after meeting your Part B deductible. Emgality and Ajovy are self-administered at home. Medicare Part B does not cover home-injected drugs. However, many Medicare Advantage plans include Part D coverage for these medications, or they may cover them under a medical benefit if prescribed by a specialist. Medicaid coverage varies by state, but most states cover at least one CGRP inhibitor when prior authorization is approved.
Average Out-of-Pocket Costs and Savings Programs
List prices for migraine prevention shots range from $600 to $700 per month for self-injections, and around $3,400 per 12-week infusion for Vyepti. Without assistance, these costs are difficult to sustain. Fortunately, manufacturer savings programs and insurance navigation tools have made them much more affordable in 2024.
Typical Monthly Costs with Assistance
- Commercial Insurance: Most patients pay between $0 and $150 per month after copay cards are applied. Eli Lilly offers the Emgality Savings Club, and Teva offers the Ajovy Copay Card. Both programs reduce copays to as low as $0 for commercially insured patients.
- Uninsured Patients: Manufacturer patient assistance programs can provide medication at no cost or a reduced rate based on income. You must apply directly through the drug manufacturer and provide proof of income.
- Medicare Part B: You will pay 20 percent of the approved infusion cost. For Vyepti, this often translates to $150 to $300 per visit, depending on facility fees.
- Medicare Part D / Medicare Advantage: Costs depend on your plan tier. Many plans place CGRP inhibitors on specialty tier 4 or 5, which can mean higher copays. Using a pharmacy benefits manager (PBM) discount card or switching to a plan with a lower specialty tier during open enrollment can save hundreds of dollars annually.
To maximize savings, always verify your plan formulary before starting. Ask your provider to submit prior authorization using the correct diagnosis codes. Use the manufacturer savings portal monthly, as copay cards must be renewed every billing cycle. If your insurance denies coverage, request a peer-to-peer review where your doctor speaks directly with the insurer's medical director.
What to Expect During Treatment
Starting a migraine prevention shot involves a few practical steps. Your provider will teach you how to store the medication, how to use the auto-injector pen, and how to rotate injection sites on your thigh, abdomen, or upper arm. Most people experience mild redness or itching at the injection site, which usually fades within a day. Constipation is the most common systemic side effect. Drinking extra water and increasing fiber intake can help manage it.
Tracking Your Progress
Prevention shots take time to reach full effect. Do not judge the treatment based on the first month. Keep a headache diary for at least 90 days. Record the number of headache days, pain severity, and any rescue medication use. Most patients notice a meaningful drop in attack frequency by week 12. If you see less than a 50 percent reduction after three months, your provider may adjust your dose or switch you to a different CGRP medication.
Long-Term Safety and Monitoring
Long-term studies show that CGRP inhibitors are well tolerated over several years. Routine blood work is not required. However, you should report any signs of severe allergic reactions, such as swelling of the face or throat, difficulty breathing, or widespread rash. These are rare but require immediate emergency care. You can also report side effects directly to the FDA MedWatch program.
Conclusion
FDA-approved migraine prevention shots have become a cornerstone of modern headache care. By targeting the CGRP pathway, these injections reduce attack frequency, lower disability, and improve daily function for thousands of Americans. Insurance coverage is widely available through prior authorization, and manufacturer savings programs keep monthly costs manageable for most patients. If you suffer from frequent or chronic migraines, gathering your medical records, checking your plan formulary, and scheduling a consultation with a neurologist or headache specialist are the best next steps. With the right support and consistent use, these treatments can restore control over your headache days.